AU2007317730B2 - Methods of treating neuronal disorders using MNTF peptides and analogs thereof - Google Patents

Methods of treating neuronal disorders using MNTF peptides and analogs thereof Download PDF

Info

Publication number
AU2007317730B2
AU2007317730B2 AU2007317730A AU2007317730A AU2007317730B2 AU 2007317730 B2 AU2007317730 B2 AU 2007317730B2 AU 2007317730 A AU2007317730 A AU 2007317730A AU 2007317730 A AU2007317730 A AU 2007317730A AU 2007317730 B2 AU2007317730 B2 AU 2007317730B2
Authority
AU
Australia
Prior art keywords
mntf
peptide
cell
disease
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007317730A
Other languages
English (en)
Other versions
AU2007317730A1 (en
Inventor
Mark S. Kindy
Pui-Yuk Dorothy Ko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genervon Biopharmaceuticals LLC
Original Assignee
Genervon Biopharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genervon Biopharmaceuticals LLC filed Critical Genervon Biopharmaceuticals LLC
Publication of AU2007317730A1 publication Critical patent/AU2007317730A1/en
Application granted granted Critical
Publication of AU2007317730B2 publication Critical patent/AU2007317730B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2007317730A 2006-11-10 2007-11-13 Methods of treating neuronal disorders using MNTF peptides and analogs thereof Ceased AU2007317730B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85802206P 2006-11-10 2006-11-10
US60/858,022 2006-11-10
PCT/US2007/023951 WO2008057609A2 (en) 2006-11-10 2007-11-13 Methods of treating neuronal disorders using mntf peptides and analogs thereof

Publications (2)

Publication Number Publication Date
AU2007317730A1 AU2007317730A1 (en) 2008-05-15
AU2007317730B2 true AU2007317730B2 (en) 2014-01-09

Family

ID=39365151

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007317730A Ceased AU2007317730B2 (en) 2006-11-10 2007-11-13 Methods of treating neuronal disorders using MNTF peptides and analogs thereof

Country Status (9)

Country Link
US (1) US8673852B2 (cg-RX-API-DMAC10.html)
EP (1) EP2086331B1 (cg-RX-API-DMAC10.html)
JP (1) JP5336384B2 (cg-RX-API-DMAC10.html)
CN (1) CN101534648B (cg-RX-API-DMAC10.html)
AU (1) AU2007317730B2 (cg-RX-API-DMAC10.html)
CA (1) CA2669658C (cg-RX-API-DMAC10.html)
DK (1) DK2086331T3 (cg-RX-API-DMAC10.html)
ES (1) ES2407454T3 (cg-RX-API-DMAC10.html)
WO (1) WO2008057609A2 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846615B2 (en) * 2008-02-21 2014-09-30 Genervon Biopharmaceuticals, LLC MNTF peptides
RU2012123642A (ru) * 2009-12-11 2014-01-20 Кейз Вестерн Ризев Юнивесити Аналоги инсулина, содержащие хлорированные аминокислоты
GB201015569D0 (en) * 2010-09-16 2010-10-27 Medical Res Council Blood assay for prions
WO2016210123A1 (en) 2015-06-26 2016-12-29 Genervon Biopharmaceuticals, LLC Methods of using gm604 in modulating als disease biomarkers leading to prognosis and therapeutic treatment for als disease
WO2018119018A1 (en) * 2016-12-23 2018-06-28 Genervon Biopharmaceuticals, LLC Methods of using gm6 in diagnosing and treating alzheimer's disease
WO2018129421A1 (en) * 2017-01-09 2018-07-12 Genervon Biopharmaceuticals, LLC A promising drug candidate for parkinson's disease
AU2019277920A1 (en) * 2018-05-31 2021-01-07 Immunity Pharma Ltd. Compositions and methods of using same for treating amyotrophic lateral sclerosis (ALS)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060052299A1 (en) * 2003-01-21 2006-03-09 Genervon Biopharmaceuticals Llc Mntf peptides and compositions and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309877B1 (en) * 1996-09-27 2001-10-30 Km Biotech, Inc. Polynucleotides encoding motoneuronotrophic factors
US6841531B2 (en) * 1996-09-27 2005-01-11 Genervon Biopharmaceuticals Llc Methods and use of motoneuronotrophic factors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060052299A1 (en) * 2003-01-21 2006-03-09 Genervon Biopharmaceuticals Llc Mntf peptides and compositions and methods of use

Also Published As

Publication number Publication date
EP2086331A4 (en) 2010-08-25
CN101534648B (zh) 2013-12-11
ES2407454T3 (es) 2013-06-12
CN101534648A (zh) 2009-09-16
WO2008057609A3 (en) 2008-12-18
WO2008057609A8 (en) 2008-08-28
AU2007317730A1 (en) 2008-05-15
JP5336384B2 (ja) 2013-11-06
CA2669658A1 (en) 2008-05-15
JP2010509345A (ja) 2010-03-25
HK1137623A1 (en) 2010-08-06
WO2008057609A4 (en) 2009-01-29
EP2086331A2 (en) 2009-08-12
CA2669658C (en) 2017-12-12
WO2008057609A2 (en) 2008-05-15
US20090048162A1 (en) 2009-02-19
EP2086331B1 (en) 2013-03-27
DK2086331T3 (da) 2013-05-27
US8673852B2 (en) 2014-03-18

Similar Documents

Publication Publication Date Title
CA2669658C (en) Methods of treating neuronal disorders using mntf peptides and analogs thereof
JP2013177388A (ja) 幹細胞のｍｎｔｆ分化および成長
AU2011314074B2 (en) ND2 peptides and methods of treating neurological disease
US20110021435A1 (en) Composition for preventing or treating brain diseases
CA2716392C (en) Mntf peptide compositions and methods of use
CN113260373B (zh) 用于诱导神经可塑性的方法和组合物
HK1137623B (en) Methods of treating neuronal disorders using mntf peptides and analogs thereof
HK1125824B (en) Mntf differentiation and growth of stem cells
HK1151242B (en) Mntf peptide compositions and methods of use

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 13 NOV 2012 TO 13 JUN 2013 IN WHICH TO PAY A CONTINUATION FEE HAS BEEN FILED .

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A CONTINUATION FEE HAS BEEN EXTENDED TO 13 JUN 2013 .

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired